Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition used for treating ovarian cancer and application thereof

A composition and technology for ovarian cancer, applied in the field of treatment of ovarian cancer, can solve problems such as unreported

Active Publication Date: 2019-12-31
HUBEI UNIV OF CHINESE MEDICINE
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, the study of tripterine and kaempferol as a combined drug regimen against ovarian cancer has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition used for treating ovarian cancer and application thereof
  • Pharmaceutical composition used for treating ovarian cancer and application thereof
  • Pharmaceutical composition used for treating ovarian cancer and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] The preparation of the pharmaceutical composition of anti-ovarian cancer, its steps are:

[0030] The active components of the pharmaceutical composition are kaempferol and tripterine, wherein the weight ratio of kaempferol to tripterine is 10:1, and the two drugs are prepared into solutions respectively, and then fully mixed evenly.

Embodiment 2

[0032] Application of the pharmaceutical composition against ovarian cancer:

[0033] (1) Cytotoxicity test and drug interaction index evaluation

[0034] Human ovarian cancer cells A2780 were treated with 1×10 5 The density of cells / well was inoculated into 96-well plates, incubated for 24 hours, and then the cells were exposed to different concentrations of kaempferol (5-40 μg / mL) and tripterine (0.625-10 μg / mL) for 24 hours. The cells were then incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) for 4 hours, and the formed formazan crystals were dissolved with 150 μL DMSO , after mixing with a micro-oscillator, use a microplate reader to measure the absorbance (OD) at 492nm, the experiment was repeated three times, and the average value was taken. The cell survival rate is equal to the ratio of the OD value of the administration group to the OD value of the blank group, that is, the cell survival rate=(OD 样品组 / OD 对照组 )×100%. Take the drug ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of ovarian cancer treatment, and discloses a pharmaceutical composition used for treating ovarian cancer and application thereof. The pharmaceutical composition used for treating ovarian cancer contains kaempferol and celastrol as active components. In the pharmaceutical composition used for treating ovarian cancer, the kaempferol and the celastrol areused in combination, wherein the kaempferol is capable of significantly enhancing antitumor effects of the celastrol by the effects of blocking cell cycles, inducing apoptosis, inhibiting cell proliferation, inhibiting cell migration and the like; and thus, the kaempferol and the celastrol synergistically take a significant effect in inhibiting growth of ovarian cancer cells.

Description

technical field [0001] The invention relates to the technical field of treating ovarian cancer, in particular to a pharmaceutical composition for treating ovarian cancer and its application. Background technique [0002] Among women over the age of 40, ovarian cancer is the most common malignancy after breast cancer. In recent years, the incidence of ovarian cancer has increased year by year. Since most patients are diagnosed in the middle and advanced stages, the mortality rate continues to rise. Currently, the main treatment for ovarian cancer is surgery combined with chemotherapy. The combination of platinum and paclitaxel is the standard chemotherapy regimen for ovarian cancer. Although it can prolong the survival time of patients, the recurrence rate is high and drug resistance is serious. The 5-year survival rate is about 30%. Therefore, it is urgent to find a way to reverse the drug resistance and more effective treatment of ovarian cancer. [0003] Celestrol (Cel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/56A61K31/352A61P15/08A61P35/00
CPCA61K31/352A61K31/56A61P15/08A61P35/00A61K2300/00
Inventor 常聪郑国华刘祖浩
Owner HUBEI UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com